VISX files more laser data and hopes for October review
This article was originally published in Clinica
VISX has filed additional data with the FDA on photorefractive keratectomy performed on some 2,000 eyes using its excimer laser system. The submission is in response to concerns raised by the FDA Ophthalmic Devices Advisory Panel meeting in October 1994 about the optimal ablation on 6 mm zones (see Clinica No 627, p 22). VISX says it is the only US company to have followed a statistically significant number of such patients for over two years.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.